Affimed (Nasdaq: AFMD) is a clinical stage biopharmaceutical company which engineers targeted immunotherapies, seeking to improve patient outcomes through the power of innate immunity. Affimed’s fit-for-purpose ROCK® platform allows innate immune engagers to be designed for specific patient populations. We are developing single and combination therapies to treat cancers.
Within our highly motivated Research and Development Team in Heidelberg, Germany, we are offering a
(Reference No. R2209)
General:
For any queries, please contact Susanne Hering (Tel: +49 6221 6743 675, e-mail: s.hering@affimed.com).
Heidelberg, May 2022